Clonal Hematopoiesis of Indeterminate Potential in Patients with Chronic Thromboembolic Pulmonary Hypertension

Running title: Liu et al.; CHIP in CTEPH

Chao Liu, MD^{1#}; Chun-Yan Cheng, MD^{1#}; Tian-Yu Lian, MD^{1,2#}; Yu-Ping Zhou, MD¹; Yin-Jian Yang, MD¹; Si-Jin Zhang, MD³; Yun-Peng Wei, MD¹; Yong-Jian Zhu, MD⁴; Lu-Hong Qiu, MD¹; Bao-Chen Qiu, MD¹; Li-Yan Ren, MD¹; Jing-Si Ma, BS⁵; Ruo-Nan Li, BS⁵; Jia Wang, BS⁶; Ying-Hui-Zi Shen, BS⁷; Zhi-Yan Han, MD⁸; Jing-Hui Li, MD⁸; Qin-Hua Zhao, MD⁹; Lan Wang, MD⁹; Xi-Qi Xu, MD¹; Kai Sun, PhD^{1,2}; Duo-Lao Wang, PhD¹⁰; Ze-Jian Zhang, PhD^{1,2*}; Zhi-Cheng Jing, MD^{1*}

Affiliations

¹Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

²Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

³Department of Cardiovascular Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China;

⁴Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;

⁵School of Pharmacy, Henan University, Henan, China;

⁶Department of Medical Laboratory, Weifang Medical University, Weifang, Shandong,

China;

⁷Department of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China;

⁸State Key Laboratory of Cardiovascular Disease and FuWai Hospital, Chinese

Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

⁹Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji

University, Shanghai, China;

¹⁰Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool,

United Kingdom

[#]These authors contributed equally to this work as the co-first authors.

^{*}Drs Zhi-Cheng Jing and Ze-Jian Zhang contributed equally to this study as the co-corresponding authors.

Address for Correspondence:

Zhi-Cheng Jing, MD, PhD

Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing 100730, China.

Tel: +86-10-69155023

E-mail: jingzhicheng@vip.163.com

Ze-Jian Zhang, PhD

Medical Research Center, State Key Laboratory of Complex Severe and Rare

> Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing 100730, China.

Tel: +86-10-69154613

E-mail:zejianzhang2018@163.com

Word Count for main text: 3059

1 Abstract

Background The pathogenesis of chronic thromboembolic pulmonary hypertension
(CTEPH) is complex and multifactorial, with growing evidence indicating the
involvement of hematologic disorders. Clonal hematopoiesis of indeterminate
potential (CHIP) has recently been associated with increased risks of both
hematologic malignancies and cardiovascular diseases. The CHIP in patients with
CTEPH and its clinical relevance remain undetermined.
Methods We performed a step-wise calling method on the next-generation

9 sequencing data from 499 CTEPH patients referred to three centers between October 2006 and December 2021 to identify CHIP mutations. We associated CHIP with all-cause mortality in patients with CTEPH. To provide potential mechanistic insights, the associations between CHIP and inflammation characteristics reflected by circulating cytokines and IgG galactosylation, a hallmark of inflammatory state in diseases were also determined.

Results Total 51 (10.2%) patients with CTEPH carried at least one CHIP mutation at 15 a variant allele frequency of $\geq 2\%$, and the most common mutations were among 16 17 DNMT3A, RUN1 and STAG2. During a mean follow-up time of 55 months, deaths occurred in 21 patients (42.9%) in the CHIP group and 105 patients (24.3%) in the 18 non-CHIP group, contributing to the 5-year survival rate of 65.3% in the CHIP group 19 20 and 81.9% in the non-CHIP group ($P \le 0.001$ for log-rank test). The association of CHIP with mortality remained robust in the fully adjusted model (HR: 3.447; 95% CI: 21 1.747 - 6.803; P < 0.001). Besides, patients in the CHIP group showed higher 22 circulating IL-1beta and IL-6 and lower IL-4 and IgG galactosylation compared with 23

- the non-CHIP group.
- 25 Conclusions CHIP is enriched in CTEPH patients and is associated with a worse
- 26 prognosis in CTEPH. Mechanically, patients in the CHIP group showed a more severe
- 27 inflammatory state.

28

- 29 Key Words: CHIP; CTEPH; inflammation; clinical outcome; high-confidence CHIP
- 30 calls strategies.

32 Non-standard Abbreviations and Acronyms

- 33 6MWD: 6-minute walking distance
- 34 BPA: balloon pulmonary angioplasty
- 35 CHIP: clonal hematopoiesis of indeterminate potential
- 36 CI: cardiac index
- 37 CTEPH: chronic thromboembolic pulmonary hypertension
- 38 MALDI-TOF-MS: matrix-assisted laser desorption/ionization time of flight mass
- 39 spectrometry
- 40 MPN: myeloproliferative neoplasms
- 41 NT-proBNP: N-terminal pro-B-type natriuretic peptide
- 42 PEA: pulmonary endarterectomy
- 43 PH: pulmonary hypertension
- 44 SvO₂: mixed venous oxygen saturation
- 45 VAF: variant allele frequency
- 46 WES: whole-exome sequencing
- 47 WGS: whole-genome sequencing
- 48 WHO FC: World Health Organization functional class
- 49

50 Clinical Perspective

51 What is new?

- 52 Clonal hematopoiesis of indeterminate potential (CHIP) mutations are enriched in
- 53 chronic thromboembolic pulmonary hypertension (CTEPH) patients, with most
- 54 common mutated genes being *DNMT3A*, *RUN1* and *STAG2*.
- CHIP is associated with worse clinical outcomes in CTEPH.
- CHIP is associated with more severe inflammation state mediated by
 myeloid as well as lymphoid cells in patients with CTEPH.
- 58

59 What are the clinical implications?

- 60 CHIP might be a risk factor for CTEPH, suggesting a relationship between
- 61 CTEPH and hematopoietic disorders.
- CHIP represented an additional disease component in CTEPH that independently
- 63 impacts prognosis.
- CHIP might be a potential target for personalized medicine and an indicator of
- 65 benefit from anti-inflammatory therapies for CTEPH patients.
- 66

67 Introduction

68 Chronic thromboembolic pulmonary hypertension (CTEPH) is a long-term and 69 life-threatening complication of pulmonary embolism, characterized by chronic 70 obstruction of pulmonary vasculature with organized and fibrotic thrombi and 71 vascular remodeling^{1,2}. Increasing evidence showed that a variety of factors including 72 inflammation³⁻⁶, coagulation dysregulation^{7,8}, genetics^{9,10}, *etc.* played important roles 73 in the development of CTEPH, suggesting the complexity and multifactorial nature of 74 pathogenesis involved.

75

Recently, there is more and more evidence supporting the involvement of hematologic 76 disorders especially myeloproliferative neoplasms (MPN) in the pathogenesis of 77 78 CTEPH, including higher rates of thrombotic events as well as recurrent venous thromboembolism in patients with MPN^{11,12}, the elevated prevalence of CTEPH in 79 MPN patients¹³, and increased mortality after pulmonary endarterectomy (PEA) in 80 CTEPH patients complicated with MPN¹⁴. Clonal hematopoiesis of indeterminate 81 potential (CHIP), defined as the presence of an expanded somatic blood cell clone in 82 persons without other hematologic diseases, is an early stage of MPN and 83 hematologic cancers^{15,16}. The presence of CHIP was shown to increase with age and is 84 significantly associated with the higher prevalence and worse prognosis of 85 cardiovascular diseases¹⁷⁻²¹. However, the relationship between CHIP and CTEPH is 86 87 yet to be investigated.

- 89 The present study aimed to assess the prevalence of CHIP-driver mutations in patients
- 90 with CTEPH and, more importantly, to associate its presence with clinical outcomes.

91

92 Method

93 Study Population

94 From October 2006 to December 2021, all consecutive patients with definite 95 diagnosis of CTEPH in three national pulmonary hypertension (PH) referral centers: 96 Shanghai Pulmonary Hospital with patients mainly from south China and FuWai Hospital and Peking Union Medical College Hospital in Beijing with patients mainly 97 from north China, were included in this study. For the diagnosis of CTEPH²², three 98 criteria had to be satisfied: (1) at least three months of effective anticoagulation, 99 100 including warfarin or new oral anticoagulant drugs (rivaroxaban or dabigatran); (2) 101 typical imaging characteristics of CTEPH assessed by computed tomography 102 pulmonary angiography and/or direct pulmonary angiography; and (3) confirmed 103 pre-capillary PH defined as mean pulmonary artery pressure of ≥ 25 mm Hg and pulmonary arterial wedge pressure of ≤ 15 mm Hg. The hemodynamic evaluation was 104 performed by right heart catheterization. Patients without available blood samples and 105 106 therefore lacking sequencing data and CHIP information were excluded. According to 107 the definition of CHIP, patients with previous hematologic cancers or other hematologic diseases were also excluded. The ethics review boards of the Shanghai 108 109 Pulmonary Hospital, FuWai Hospital and Peking Union Medical College Hospital 110 approved the protocols. All patients provided written informed consent. The study

111 complies with the Declaration of Helsinki.

112

113 Next-Generation Sequencing

Genomic DNA samples were either whole-exome sequencing (WES) or 114 whole-genome sequencing (WGS) according to standard protocols. The WGS was 115 performed at WuXi Apptech (Shanghai, China) using a PCR-free library preparation 116 117 and paired-end $(2 \times 150 \text{ bp})$ sequencing on the HiSeq X Ten platform (Illumina, Inc., 118 San Diego, CA, USA) to yield a minimum of $35 \times$ coverage. The WES was performed at Novogene Corporation (Beijing, China) using the Agilent SureSelect 119 Human All Exon kit (50 MB or 60 MB) and sequencing on the Illumina HiSeq 120 121 instruments to provide a mean coverage of more than $100 \times on$ the target regions of 122 every sample. Prior to sequencing, samples were randomized to minimize batch 123 effects. We used two sequencing platforms (WES and WGS) to genotype the CTEPH 124 cases. To reduce systematic errors and alignment artifacts of the two sequencing platform, we restricted our call for variants to RefSeq coding sequences and called 125 126 WGS together with WES using very strict criteria detailed below.

127

128 Variant Calling and Annotation Strategies

We used previously established methods to identify CHIP, which were described in detail elsewhere²³. In the first step, Mutect2, Genome Analysis Toolkit was used as a somatic variant calling pipeline to scan aligned sequencing files for putative somatic variants²⁴. Briefly, Mutect2 was run in 'tumor-only' mode with default parameters,

over a list of variants within 74 driver genes previously associated with CHIP¹⁹ (Table 133 S1), as well as those new variants reported as somatic mutations in hematologic 134 cancers at least seven times in COSMIC. Only non-synonymous exonic or splicing 135 variants were considered. We removed variants with a total read depth of less than 15, 136 variants with minimum read depth for the alternate allele of less than three, and 137 138 variants lacking variant support in both forward and reverse sequencing reads. We 139 also removed variants below the 2% variant allele frequency (VAF) threshold 140 conventionally used to define CHIP. Variants occurring in 5% of all studied patients were considered probable recurrent sequencing artifacts. For this, the association of 141 142 each variant group with age, an established strong correlate of CHIP was tested. 143 Variants that were not associated with age at even a suggestive significance of P < P0.10 were removed from the dataset as they were suspected to represent sequencing 144 artifacts²³. To filter out potential germline variants, we conducted a binomial test 145 146 across all variants to determine whether the measured read depth for the variant is 147 statistically different from half of the sum of all sequencing reads at that site, as would 148 be true for heterozygous germline variants. Variants that failed the binomial test at P <0.01 would be removed from the dataset. 149

150

151 Data Collection and Follow-up

Data on patient characteristics at first admission for CTEPH diagnosis were collected,
including demographic information, clinical symptoms, medical history, World Health
Organization functional class (WHO FC), 6-minute walking distance (6MWD),

155	hematological testing, invasive hemodynamics, and treatments. Blood samples for
156	genetic sequencing and circulating inflammation characteristics testing were collected
157	during the first diagnostic right heart catheterization.
158	
159	Patients were followed up via clinic visits or by phone or internet interviews, and the
160	observation period was from the initial diagnosis of CTEPH to January 2022 or the
161	latest visit. The single clinical endpoint was all-cause mortality.
162	
163	Inflammatory Characteristics Measurement
164	The levels of four circulating inflammatory markers were determined in the plasma of
165	CTEPH patients using commercially available bead-based multiplex Luminex assays
166	employing the Luminex 200 system for acquisition. Standard curves were included in
167	the kits. The procedure was according to the manufacturer's protocol and previous
168	literature ²⁵ .
169	
170	The inflammatory marker of IgG Gal-ratio (distribution of IgG galactosylation)
171	profiling is performed according to published protocols ^{26,27} . Briefly, IgG was isolated
172	from plasma samples using 96-well Protein A Spin Plates, and the glycans on IgG

were enzymatically released by PNGase F. The released IgG N-glycans were then
purified by porous graphitized carbon and analyzed by matrix-assisted laser
desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) (Bruker
Daltonics, Bremen). The processing of MALDI-TOF-MS raw data and IgG N-glycan

identification was according to our previous work^{26,27}. The inflammatory marker of IgG Gal-ratio was obtained by calculating the relative intensities of agalactosylated (H3N4F1, G0) vs. monogalactosyl (H4N4F1, G1) and digalactosyl (H5N4F1, G2) N-glycans according to the formula of Gal-ratio = $G0/(G1 + 2 \times G2)$ as previously reported^{26,27}.

182

183 Statistical Analysis

184 Adherence to a Gaussian distribution was determined using the Kolmogorov-Smirnov test. Normally distributed data were described as mean SD, and the independent 185 186 samples Student's t-test was used to compare continuous variables between two groups. In the case of skewed distribution, data were described as median (IQR) and 187 188 the nonparametric Mann-Whitney U-test was used for group comparisons. Qualitative 189 variables were described with n (%) and analyzed using the Fisher exact test. 190 Multivariable Cox proportional-hazards regression models were used to calculate 191 hazard ratios (HR) for event rates, whereas Kaplan-Meier event rates and log-rank 192 tests were used to compare survival estimates. All reported tests were 2-tailed, and the threshold for statistical significance was 0.05. The analyses were performed with 193 194 SPSS 26 and GraphPad Prism 8.

195

196 **Results**

197 Study Population and baseline characteristics

198 The screening and inclusion of patients with CTEPH are presented in Figure 1.

199	Initially, 567 patients suspected of having CTEPH were screened. Among them, eight
200	patients were excluded due to having other aetiologies of pulmonary artery stenosis
201	(four with pulmonary arteritis, two with congenital pulmonary artery stenosis and two
202	with pulmonary artery sarcomas). Fifty-four patients without available blood samples
203	and six patients with previous hematologic diseases were further excluded. Finally,
204	499 patients were included in the analysis.
205	
206	Baseline characteristics are provided in Table 1: 248 patients (49.7%) were male;
207	mean patient age was 54.4 \pm 14.8 years; 468 patients (93.8%) received PH-targeted
200	dense there are 272 metionets (54.70/) and dense to DEA an DDA to structure to Succification

drugs therapy; 273 patients (54.7%) underwent PEA or BPA treatment. Specifically,

209 198 patients (39.7%) underwent BPA, 106 patients (21.2%) underwent PEA and 31

210 patients (6.2%) received BPA and PEA bridging therapy.

211

212 **Prevalence of CHIP**

Fifty-one (10.2%) patients were found to carry one or more of the CHIP mutations at a VAF of \geq 2%, with six of them carrying two mutations (Figure 2A). With an identical analysis strategy, CTEPH patients in our cohort presented a higher prevalence than the healthy population of comparative age in the "All of Us" Research Program, suggesting that CHIP mutations are enriched in patients with CTEPH.

219

A total of 52 mutations in 25 genes were identified, and the somatic mutations most

221	commonly occurred in the genes DNMT3A (11 patients), RUNX1 (six patients),
222	STAG2 (five patients), followed by TET2, ASXL1, BCOR, EP300 and GNAS (three
223	patients each). Mutations in CREBBP, PHIP and PRPF40B were identified in two
224	patients, and 14 other genes associated with CHIP were found to be mutated in
225	individual patients (Figure 2B). A detailed list including types of mutations and VAFs
226	is provided in the Supplemental Material, Table S2.

227

Compared with non-carriers, patients with CHIP mutations were older, had significantly higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) and D-dimer levels, decreased cardiac index (CI), mixed venous oxygen saturation (SvO2), and 6MWD, and more compromised cardiac function. Other clinical characteristics as well as treatment regimens showed no difference between the two groups (Table 1).

233

234 Follow-up

235 With 18 patients lost for follow-up, a total of 481 patients were further included in the 236 survival analysis. During a median follow-up of 55 months, deaths occurred in 21 237 patients (42.9%) in the CHIP group and 105 patients (24.3%) in the non-CHIP group, contributing to the 5-year survival rate of 65.3% in the CHIP group and 81.9% in the 238 239 non-CHIP group (P < 0.001 for the log-rank test) (Figure 3). In univariate analysis, the presence of CHIP mutations with a VAF of $\geq 2\%$ was significantly associated with 240 all-cause mortality with HR of 2.290 (95% CI: 1.428 - 3.672; P < 0.001). After 241 adjustment for age and sex or in combination with clinical and hemodynamic 242

243	characteristics, the association remained robust (HR: 2.161, 95% CI: 1.342 - 3.479, P
244	= 0.002; HR: 2.636, 95% CI: 1.415 - 4.912, $P = 0.002$). Finally, by multivariate Cox
245	proportional regression analysis, including age, sex, clinical and hemodynamic
246	characteristics and treatment regimens (whether or not patients underwent PEA/BPA
247	treatments) as covariants, all-cause death still remained independently associated with
248	the presence of somatic mutations associated with CHIP (HR: 3.447; 95% CI: 1.747 -
249	6.803; $P < 0.001$) (Table 3). There was no evidence of effect modification across
250	different treatment groups (P for interaction = 0.886).

251

252 Potential Mechanistic Insights

Mechanistically, the most common mutated genes in CHIP, DNMT3A and TET2, were 253 experimentally shown to regulate the inflammatory potential of circulating 254 leucocytes^{19,28-30}. Meanwhile, various immune cells as well as chemokines were 255 enriched in plasma or thrombotic lesions of CTEPH patients³⁻⁶. In the present study, 256 257 multiple inflammatory mediators including TNF-alpha, IL-1beta, IL-4 and IL-6 were measured for 20 patients carrying CHIP mutations and 201 patients without such. In 258 line with previous works^{31,32}, our data showed elevated pro-inflammatory cytokines 259 260 IL-1beta (P = 0.009), IL-6 (P = 0.001) and TNF-alpha (P = 0.06) and decreased anti-inflammatory cytokine IL-4 (P = 0.008) in the CHIP group of CTEPH patients 261 (Figure 3). 262

263

264 Besides, our previous study suggested that IgG N-glycan characteristics of CTEPH

265	patients presented an obvious pro-inflammatory phenotype (decreased proportion of
266	IgG galactosylation [higher IgG Gal-ratio]) ³³ . Decreased IgG galactosylation has been
267	reported to be a hallmark of inflammation ³⁴ . In the present study, baseline IgG glycan
268	characteristics were analysed in a subset of 221 patients, of whom 20 carried CHIP
269	mutations. Glycan analysis was performed without knowing the CHIP status of the
270	patients. We found the level of H5N4F1 ($P = 0.038$) was significantly lower and the
271	levels of H3N4F1 ($P = 0.014$) and IgG Gal-ratio ($P = 0.008$) (Gal-ratio =
272	H3N4F1/[H4N4F1+2*H5N4F1]) were significantly higher in the CHIP group than in
273	the non-CHIP group.

274

275 **Discussion**

The results of the present study significantly extend previous reports showing that 276 277 CHIP-driver mutations are associated with the risk and prognosis of patients with cardiovascular diseases including coronary artery disease¹⁹, chronic heart failure^{35,36} 278 and degenerative aortic valve stenosis³⁷. CHIP-related studies in PH were quite rare 279 and previous studies focused only on the relationship between specific driver 280 mutations (TET2 and JAK2V617F)^{10,38,39} and the risk of PH. To the best of our 281 knowledge, this is the first study focused on a well-defined group of CTEPH patients 282 to reveal an overview of CHIP-driver genes mutation with non-biased genome 283 sequencing and to investigate its relationship with the prognosis of CTEPH patients. 284 285 Our results demonstrate that CHIP-driver mutations occurred frequently in this patient population, were associated with more severe inflammatory states, and conferred 286

287 profoundly worse outcomes.

288

CHIP mutations can be identified in peripheral blood samples sequenced using 289 290 approaches that cover the whole genome, whole exome or targeted genetic regions; 291 however, differentiating true CHIP mutations from sequencing artifacts and germline 292 variants is a considerable bioinformatic challenge. To increase the accuracy of CHIP calls, we referred to a step-wise method raised by Bick et al.²³. This method combines 293 294 filtering based on sequencing metrics, variant annotation, and population-based associations method to increase the fidelity of CHIP calls. With an identical calling 295 296 approach, the prevalence of CHIP mutations in CTEPH patients is higher than in the 297 age-paired healthy population in the "All of Us" Research Program, suggesting that 298 CHIP mutations are enriched in patients with CTEPH. Interestingly, the most common 299 mutations in this population are DNMT3A, RUNX1 and STAG2, followed by TET2 300 and other mutations, presenting a bit little different scenario from most previous 301 reports. This difference could be blamed on the discrepancy in either diseases studied, 302 population or sequencing and calling approaches.

303

In this study, the association of CHIP with mortality was observed in a univariate model. Consistent with previous studies, patients in the CHIP group are significantly older than the non-CHIP group, and CHIP effects were robust after adjustment for age and sex. NT-proBNP, CI, SvO₂, WHO FC and 6MWD showed significant differences between the CHIP and non-CHIP groups, which may simply be a reflection of the age

difference between the groups. WHO FC, 6MWD, NT-proBNP, SvO₂, right atrial pressure, CI, pulmonary vascular resistance and treatment regimens as well as age and sex were used to further adjust the model. Importantly, all-cause death still remained independently associated with the presence of somatic mutations associated with CHIP.

314

315 Recent studies based on CANTOS (Canakinumab Anti-Inflammatory Thrombosis 316 Outcome Study) and UK Biobank reported that patients harboring TET2 mutations showed a statistically significant reduced risk for incident major cardiovascular events 317 318 by canakinumab, indicating that some patients with CHIP mutations especially TET2 could potentially benefit from targeted anti-inflammatory therapy^{40,41}. This is in line 319 320 with previous works demonstrating increased levels of IL-6 and IL-1beta in Tet2 loss-of-function mouse models^{19,28}. In this study, levels of IL-1beta and IL-6 are 321 322 higher in CHIP patients, implicating targeted anti-inflammatory therapy might benefit 323 the subgroup of CTEPH patients with CHIP mutations.

324

Aside from inflammation mediated by myeloid cells, lymphoid cell-related immune activation was also found to be involved in CHIP-related pro-inflammatory effects. Mas-Peiro *et al.* reported that Th17 to regulatory T-cell ratios were augmented in aortic stenosis patients with *DNMT3A* mutations³⁷. What's more, circulating monocytes and T cells of patients with heart failure harboring clonal hematopoiesis-driver mutations in *DNMT3A* exhibit a highly inflamed transcriptome⁴².

These may be in line with different lineage restrictions, which indicate a myeloid bias for *TET2*, but multipotent stem cell origin for *DNMT3A*⁴³. *DNMT3A*-driven mutations prevailed in the patients of our cohort, so we further test the pro-inflammatory effects of CHIP from lymphoid perspectives.

335

336 IgG, the most abundant glycoprotein secreted by lymphoid cells and the main effector of humoral immunity⁴⁴, plays a central role in human immune responses and is 337 338 involved in inflammatory pathways. IgG regulates systemic inflammatory homeostasis at multiple levels primarily by its N-glycans⁴⁵. Decreased galactosylation 339 of IgG N-glycans is reported as a hallmark of inflammation³⁴. Moreover, our 340 preliminary research has found that IgG N-glycome in CTEPH presented a 341 pro-inflammatory phenotype (up-regulated IgG Gal-ratio representing decreased IgG 342 343 galactosylation), compared with healthy controls and IgG Gal-ratio is positively correlated with the level of NT-proBNP³³. In this study, we found that patients in the 344 345 CHIP group showed a more severe inflammatory state reflected by up-regulated IgG Gal-ratio, compared with that in the non-CHIP group, suggesting a probable 346 347 relationship between CHIP and secreted IgG antibody phenotype. However, the causality and directionality of the link between the pro-inflammatory function of IgG 348 349 and CHIP still require further investigation.

350

351 Limitations

352 Firstly, the current study focused on a thoroughly annotated clinical cohort of patients

353	with CTEPH. Although this is a comparably large clinical cohort of patients with
354	CTEPH, the sample size is still limited. Secondly, considering the sensitivity of
355	next-generation sequencing, the presence of CHIP was defined as the occurrence of
356	mutations with a VAF of at least 0.02 in this study. However, the results of previous
357	studies indicate that even lower VAFs may be associated with the development of
358	various cardiovascular diseases. Further studies with more sensitive sequencing
359	approaches are required to identify more specific thresholds of VAF for CTEPH
360	patients. Lastly, the involvement of CHIP in the pathogenesis of CTEPH still needs to
361	be further clarified in the future.
362	
363	Conclusion
364	Our data demonstrated that CHIP mutations were enriched in CTEPH patients and
365	represented an additional disease component in this disease that independently
366	impacts prognosis.
367	
368	Acknowledgements
369	Author Contributions
370	Conception and design: ZCJ, ZJZ, CL, TYL, CYC; Analysis and interpretation of data:
371	CL, ZJZ, LHQ, BCQ, LYR, JSM; Drafting of the manuscript: CL, ZJZ, YJY, CYC,
372	YPW, YJZ; critical revision of the manuscript for important intellectual content: ZCJ,
373	YPZ, TYL, SJZ; final approval of the manuscript: all authors; statistical expertise:
374	DLW, KS; obtaining of research funding: ZCJ, ZJZ, YPZ; acquisition of data: ZYH,

375 JHL, QHZ, LW, XQX, RNL, JW.

376

377 **Sources of Funding**

- This work was supported by grants from the CAMS Innovation Fund for Medical 378
- Sciences (2021-I2M-1-018), National Key Research and Development Program of 379
- 380 China (2022YFC2703902), National Natural Science Foundation of China
- 381 (82241020), and National High Level Hospital Clinical Research Funding
- (2022-PUMCH-B-099 and 2022-PUMCH-A-200). 382

383

- Disclosures 384
- 385 None

386

387 **Supplemental Materials**

388 Tables S1-S2

389

390 References

1. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, Jenkins D, 391

Kim NH, Humbert M, Jais X, et al. ERS statement on chronic thromboembolic 392

- 393 pulmonary hypertension. Eur J. 2021;57. doi: Respir 10.1183/13993003.02828-2020
- 394
- 395 2. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka
- M, Williams PG, Souza R. Haemodynamic definitions and updated clinical 396

- 397 classification of pulmonary hypertension. Eur Respir J. 2019;53. doi:
- 398 10.1183/13993003.01913-2018
- 399 3. Quarck R, Wynants M, Verbeken E, Meyns B, Delcroix M. Contribution of
 inflammation and impaired angiogenesis to the pathobiology of chronic
 thromboembolic pulmonary hypertension. *Eur Respir J.* 2015;46:431-443. doi:
- 402 10.1183/09031936.00009914
- 403 4. Bochenek ML, Rosinus NS, Lankeit M, Hobohm L, Bremmer F, Schutz E,
- 404 Klok FA, Horke S, Wiedenroth CB, Munzel T, et al. From thrombosis to 405 fibrosis in chronic thromboembolic pulmonary hypertension. *Thromb Haemost*.

406 2017;117:769-783. doi: 10.1160/TH16-10-0790

- 5. Zabini D, Heinemann A, Foris V, Nagaraj C, Nierlich P, Balint Z, 407 408 Kwapiszewska G, Lang IM, Klepetko W, Olschewski H, et al. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary 409 410 hypertension patients. Eur Respir J. 2014;44:951-962. doi: 411 10.1183/09031936.00145013
- 412 6. Yang M, Deng C, Wu D, Zhong Z, Lv X, Huang Z, Lian N, Liu K, Zhang Q.
 413 The role of mononuclear cell tissue factor and inflammatory cytokines in
 414 patients with chronic thromboembolic pulmonary hypertension. *J Thromb*415 *Thrombolysis*. 2016;42:38-45. doi: 10.1007/s11239-015-1323-2
- Zia A, Russell J, Sarode R, Veeram SR, Josephs S, Malone K, Zhang S,
 Journeycake J. Markers of coagulation activation, inflammation and
 fibrinolysis as predictors of poor outcomes after pediatric venous

- 419 thromboembolism: A systematic review and meta-analysis. *Thromb Res.*
- 420 2017;160:1-8. doi: 10.1016/j.thromres.2017.10.003
- 421 8. Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Numano K,
- 422 Al-Mamun E, Siddique MA, Sunamura S, et al. Activated TAFI Promotes the
- 423 Development of Chronic Thromboembolic Pulmonary Hypertension: A
- 424 Possible Novel Therapeutic Target. Circ Res. 2017;120:1246-1262. doi:
- 425 10.1161/CIRCRESAHA.117.310640
- 426 9. Yaoita N, Satoh K, Satoh T, Shimizu T, Saito S, Sugimura K, Tatebe S,
- Yamamoto S, Aoki T, Kikuchi N, et al. Identification of the Novel Variants in
 Patients With Chronic Thromboembolic Pulmonary Hypertension. *J Am Heart Assoc*. 2020;9:e015902. doi: 10.1161/JAHA.120.015902
- 430 10. Eichstaedt CA, Verweyen J, Halank M, Benjamin N, Fischer C, Mayer E,
- 431 Guth S, Wiedenroth CB, Egenlauf B, Harutyunova S, et al. Myeloproliferative
- Diseases as Possible Risk Factor for Development of Chronic
 Thromboembolic Pulmonary Hypertension-A Genetic Study. *Int J Mol Sci.*2020;21. doi: 10.3390/ijms21093339
- Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis,
 microvascular disease, and hemorrhage in the myeloproliferative neoplasms.

437 Blood. 2021;137:2152-2160. doi: 10.1182/blood.2020008109

- 438 12. De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, Randi ML,
- Elli E, Finazzi MC, Finazzi G, Zetterberg E, et al. High rate of recurrent
 venous thromboembolism in patients with myeloproliferative neoplasms and

441		effect of prophylaxis with vitamin K antagonists. Leukemia.
442		2016;30:2032-2038. doi: 10.1038/leu.2016.85
443	13.	Venton G, Turcanu M, Colle J, Thuny F, Chebrek S, Farnault L, Mercier C,
444		Ivanov V, Fanciullino R, Suchon P, et al. Pulmonary hypertension in patients
445		with myeloproliferative neoplasms: A large cohort of 183 patients. Eur J
446		Intern Med. 2019;68:71-75. doi: 10.1016/j.ejim.2019.08.004
447	14.	Genty T, Wirth C, Humbert M, Fadel E, Stephan F. Pulmonary
448		Endarterectomy in Patients With Myeloproliferative Neoplasms. Chest.
449		2022;161:552-556. doi: 10.1016/j.chest.2021.09.007
450	15.	Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP,
451		Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction
452		from myelodysplastic syndromes. <i>Blood</i> . 2015;126:9-16. doi:
453		10.1182/blood-2015-03-631747
454	16.	Leiva O, Hobbs G, Ravid K, Libby P. Cardiovascular Disease in
455		Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art
456		Review. JACC CardioOncol. 2022;4:166-182. doi:
457		10.1016/j.jaccao.2022.04.002

- 17. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. 458 Science. 2019;366. doi: 10.1126/science.aan4673 459
- 18. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, 460 Lindsley RC, Mermel CH, Burtt N, Chavez A, et al. Age-related clonal 461 hematopoiesis associated with adverse outcomes. N Engl J Med. 462

463 2014;371:2488-2498. doi: 10.1056/NEJMoa1408617

- 464 19. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, et al. Clonal Hematopoiesis and Risk of 465 Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377:111-121. doi: 466 10.1056/NEJMoa1701719 467 468 20. Honigberg MC, Zekavat SM, Niroula A, Griffin GK, Bick AG, Pirruccello JP, 469 Nakao T, Whitsel EA, Farland LV, Laurie C, et al. Premature Menopause, 470 Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. Circulation. 471 2021;143:410-423. doi: 10.1161/CIRCULATIONAHA.120.051775 472 473 21. Yu B, Roberts MB, Raffield LM, Zekavat SM, Nguyen NQH, Biggs ML, 474 Brown MR, Griffin G, Desai P, Correa A, et al. Supplemental Association of 475 Clonal Hematopoiesis With Incident Heart Failure. J Am Coll Cardiol. 476 2021;78:42-52. doi: 10.1016/j.jacc.2021.04.085 477 22. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, 478 Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task 479 480 Force for the Diagnosis and Treatment of Pulmonary Hypertension of the
- (ERS): Endorsed by: Association for European Paediatric and Congenital
 Cardiology (AEPC), International Society for Heart and Lung Transplantation

European Society of Cardiology (ESC) and the European Respiratory Society

484 (ISHLT). *Eur Heart J*. 2016;37:67-119. doi: 10.1093/eurheartj/ehv317

481

485	23.	Vlasschaert	C, Mack	Τ,	Heimlich	JB,	Niroula	А,	Uddin	MM,	Weinstock J	J,
-----	-----	-------------	---------	----	----------	-----	---------	----	-------	-----	-------------	----

- 486 Sharber B, Silver AJ, Xu Y, Savona M, et al. A practical approach to curate
- 487 clonal hematopoiesis of indeterminate potential in human genetic data sets.

488 Blood. 2023;141:2214-2223. doi: 10.1182/blood.2022018825

- 489 24. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C,
- Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic
 point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol*.
- 492 2013;31:213-219. doi: 10.1038/nbt.2514
- Tang J, Liu H, Sun M, Zhang X, Chu H, Li Q, Prokosch V, Cui H. Aqueous
 Humor Cytokine Response in the Contralateral Eye after First-Eye Cataract
 Surgery in Patients with Primary Angle-Closure Glaucoma, High Myopia or
- 496 Type 2 Diabetes Mellitus. *Front Biosci (Landmark Ed)*. 2022;27:222. doi:
 497 10.31083/j.fbl2707222
- 497 10.31083/j.fbl2707222
- Ren S, Zhang Z, Xu C, Guo L, Lu R, Sun Y, Guo J, Qin R, Qin W, Gu J.
 Distribution of IgG galactosylation as a promising biomarker for cancer
 screening in multiple cancer types. *Cell Res.* 2016;26:963-966. doi:
- 501 10.1038/cr.2016.83
- 502 27. Qian Y, Wang Y, Zhang X, Zhou L, Zhang Z, Xu J, Ruan Y, Ren S, Xu C, Gu J.
- Quantitative analysis of serum IgG galactosylation assists differential
 diagnosis of ovarian cancer. J Proteome Res. 2013;12:4046-4055. doi:
 10.1021/pr4003992
- 506 28. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC,

507		Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, et al. Clonal
508		hematopoiesis associated with TET2 deficiency accelerates atherosclerosis
509		development in mice. Science. 2017;355:842-847. doi:
510		10.1126/science.aag1381
511	29.	Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K.
512		CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in
513		Clonal Hematopoiesis and Cardiovascular Disease. Circ Res.
514		2018;123:335-341. doi: 10.1161/CIRCRESAHA.118.313225
515	30.	Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga
516		MA, Yoshiyama M, Goukassian D, Cooper MA, et al. Tet2-Mediated Clonal
517		Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the
518		IL-1beta/NLRP3 Inflammasome. J Am Coll Cardiol. 2018;71:875-886. doi:
519		10.1016/j.jacc.2017.12.037
520	31.	Bohme M, Desch S, Rosolowski M, Scholz M, Krohn K, Buttner P, Cross M,
521		Kirchberg J, Rommel KP, Poss J, et al. Impact of Clonal Hematopoiesis in
522		Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction. J
523		Am Coll Cardiol. 2022;80:1545-1556. doi: 10.1016/j.jacc.2022.08.740
524	32.	Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM.
525		Association of Clonal Hematopoiesis of Indeterminate Potential With
526		Inflammatory Gene Expression in Patients With Severe Degenerative Aortic
527		Valve Stenosis or Chronic Postischemic Heart Failure. JAMA Cardiol.
528		2020;5:1170-1175. doi: 10.1001/jamacardio.2020.2468

529	33.	Zhang Z, Wang H, Lian T, Zhou Y, Xu X, Guo F, Wei Y, Li J, Sun K, Liu C, et
530		al. Human Plasma Immunoglobulin G N-Glycome Profiles Reveal a
531		Pro-Inflammatory Phenotype in Chronic Thromboembolic Pulmonary
532		Hypertension: A Cross-Sectional Study of Two Independent Cohorts. SSRN
533		preprint. 2023. doi: 10.2139/ssrn.4366881
534	34.	Plomp R, Ruhaak LR, Uh HW, Reiding KR, Selman M, Houwing-Duistermaat
535		JJ, Slagboom PE, Beekman M, Wuhrer M. Subclass-specific IgG
536		glycosylation is associated with markers of inflammation and metabolic health.
537		Sci Rep. 2017;7:12325. doi: 10.1038/s41598-017-12495-0
538	35.	Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K,
539		Schmid T, Brune B, Wagner S, Serve H, et al. Association of Mutations
540		Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic
541		Heart Failure. JAMA Cardiol. 2019;4:25-33. doi:
542		10.1001/jamacardio.2018.3965
543	36.	Pascual-Figal DA, Bayes-Genis A, Diez-Diez M, Hernandez-Vicente A,
544		Vazquez-Andres D, de la Barrera J, Vazquez E, Quintas A, Zuriaga MA,
545		Asensio-Lopez MC, et al. Clonal Hematopoiesis and Risk of Progression of
546		Heart Failure With Reduced Left Ventricular Ejection Fraction. J Am Coll
547		Cardiol. 2021;77:1747-1759. doi: 10.1016/j.jacc.2021.02.028

Mas-Peiro S, Hoffmann J, Fichtlscherer S, Dorsheimer L, Rieger MA,
Dimmeler S, Vasa-Nicotera M, Zeiher AM. Clonal haematopoiesis in patients
with degenerative aortic valve stenosis undergoing transcatheter aortic valve

551		implantation. Eur Heart J. 2020;41:933-939. doi: 10.1093/eurheartj/ehz591						
552	38.	Potus F, Pauciulo MW, Cook EK, Zhu N, Hsieh A, Welch CL, Shen Y, Tian L,						
553		Lima P, Mewburn J, et al. Novel Mutations and Decreased Expression of the						
554		Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension. Circulation.						
555		2020;141:1986-2000. doi: 10.1161/CIRCULATIONAHA.119.044320						
556	39.	Kimishima Y, Misaka T, Yokokawa T, Wada K, Ueda K, Sugimoto K,						
557		Minakawa K, Nakazato K, Ishida T, Oshima M, et al. Clonal hematopoiesis						
558		with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation						
559		in lung neutrophils. Nat Commun. 2021;12:6177. doi:						
560		10.1038/s41467-021-26435-0						
561	40.	Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H,						
562		D'Aco K, Fernandez A, Wache-Mainier C, et al. TET2-Driven Clonal						
563		Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the						
564		CANTOS Randomized Clinical Trial. JAMA Cardiol. 2022;7:521-528. doi:						
565		10.1001/jamacardio.2022.0386						
566	41.	Vlasschaert C, Heimlich JB, Rauh MJ, Natarajan P, Bick AG. Interleukin-6						
567		Receptor Polymorphism Attenuates Clonal Hematopoiesis-Mediated Coronary						
568		Artery Disease Risk Among 451 180 Individuals in the UK Biobank.						
569		<i>Circulation.</i> 2023;147:358-360. doi:						
570		10.1161/CIRCULATIONAHA.122.062126						
571	42.	Abplanalp WT, Cremer S, John D, Hoffmann J, Schuhmacher B, Merten M,						
572		Rieger MA, Vasa-Nicotera M, Zeiher AM, Dimmeler S. Clonal						

573		Hematopoiesis-Driver	DNMT3A Mutations	s Alter Immune Cells in	Heart
574		Failure. Circ	Res.	2021;128:216-228.	doi:
575		10.1161/CIRCRESAH	A.120.317104		
576	43.	Buscarlet M, Provost S	, Zada YF, Bourgoin V	V, Mollica L, Dube MP, Buse	que L.
577		Lineage restriction an	alyses in CHIP indic	ate myeloid bias for TET	2 and
578		multipotent stem cell	origin for DNMT3A	. Blood. 2018;132:277-280). doi:
579		10.1182/blood-2018-0	1-829937		
580	44.	Vidarsson G, Dekkers	s G, Rispens T. IgG	subclasses and allotypes:	from
581		structure to effecto	or functions. Front	Immunol. 2014;5:520.	doi:
582		10.3389/fimmu.2014.0	0520		
583	45.	Gudelj I, Lauc G, Pez	zer M. Immunoglobul	in G glycosylation in agin	g and
584		diseases. Cell Immunol	. 2018;333:65-79. doi:	: 10.1016/j.cellimm.2018.07	.009
585					

	Total cohort	CHIP	Non-CHIP	Р
	(n = 499)	(n = 51)	(n = 448)	value
Demographic variables				
Age, y	54.4 ± 14.8	58.4 ± 13.4	54.0 ± 14.9	0.045
Male	248 (49.7)	23 (44.9)	225 (50.2)	0.488
Diagnostic delay, mo	24.6 (11.8 - 60.9)	26.2 (11.6 - 61.7)	24.5 (11.6 - 60.9)	0.962
Blood group non-O	395 (79.2)	42 (81.8)	353 (78.8)	0.553
Prior VTE history	360 (72.1)	39 (76.5)	321 (71.7)	0.467
Recurrent VTE history	34 (6.8)	4 (7.8)	30 (6.7)	0.758
Comorbid conditions				
Thrombophilia disorders	38 (7.6)	3 (5.9)	35 (7.8)	0.622
APS	30 (6.0)	3 (5.9)	27 (6.0)	0.967
Pacemaker	1 (0.2)	0 (0.0)	1 (0.2)	0.736
Splenectomy	4 (0.8)	0 (0.0)	4 (0.9)	0.498
Active cancer	6 (1.2)	0 (0.0)	6 (1.3)	0.406
Renal insufficiency	23 (4.6)	4 (7.8)	19 (4.2)	0.245
Coronary artery disease	29 (5.8)	4 (7.8)	25 (5.6)	0.513
Ischemic stroke	27 (5.4)	1 (2.0)	26 (5.8)	0.25
Diabetes	23 (4.6)	2 (3.9)	21 (4.7)	0.805
Anemia	26 (5.2)	3 (5.9)	23 (5.1)	0.82
Clinical variables				
WHO FC (III - IV)	320 (64.1)	42 (82.4)	278 (62.1)	0.004
6MWD, m	384.2 ± 116.3	335.7 ± 127.0	389.3 ± 114.2	0.013
NT-proBNP, pg/mL	1,161.0 (292.0 - 2,863.3)	1,886.0 (754.8 - 3,787.9)	1,104.5 (268.0 - 2,820.0)	0.019
D-dimer, ng/mL	450.0 (200.0 - 1020.0)	610.0 (330.0 - 1540.0)	420.0 (190.0 - 970.0)	0.012
Hgb, mg/L	146.8 ± 21.5	143.1 ± 23.1	147.2 ± 21.3	0.348
Plt, /μL	198.9 ± 70.3	194.1 ± 72.6	199.5 ± 70.1	0.663

atomisti f CTEDII otionto tified 4:. Table 1 Ch CIIID . . . 58

WBC, /mL	6.3 ± 2.0	6.4 ± 2.2	6.3 ± 2.0	0.691
Hemodynamics				
RAP, mm Hg	8.3 ± 5.4	9.7 ± 6.9	8.1 ± 5.2	0.142
mPAP, mm Hg	49.1 ± 12.1	48.8 ± 10.9	49.2 ± 12.3	0.839
PAWP, mm Hg	9.8 ± 3.4	10.3 ± 4.0	9.7 ± 3.3	0.324
PVR, Wood units	9.5 ± 4.7	10.1 ± 4.3	9.5 ± 4.7	0.382
CI, L/min/m ²	2.6 ± 0.7	2.3 ± 0.5	2.6 ± 0.7	0.015
SvO ₂ , %	62.1 ± 8.5	58.4 ± 10.0	62.5 ± 8.3	0.002
Treatments				
Drugs approved for PAH	468 (93.8)	48 (94.1)	420 (93.8)	0.918
BPA or PEA	273 (54.7)	25 (49.0)	248 (55.4)	0.389
BPA	198 (39.7)	18 (35.3)	180 (40.2)	0.499
PEA	106 (21.2)	13 (25.5)	93 (20.8)	0.434

588 P values in bold represent statistical significance of Student's t-test or Mann-Whitney U-test for quantitative

589 variables and fisher exact test for qualitative variables between CHIP and non-CHIP groups.


590	6MWD = 6-minute walking distance; APS = antiphospholipid syndrome; BPA = balloon pulmonary angioplasty;
591	CHIP = clonal hematopoiesis of indeterminate potential;CI = cardiac index; CTEPH = chronic thromboembolic
592	pulmonary hypertension; Hgb = hemoglobin; mPAP = mean pulmonary artery pressure; NT-proBNP = N-terminal
593	pro-B-type natriuretic peptide; PAWP = pulmonary artery wedge pressure; PEA = pulmonary endarterectomy; PH
594	= pulmonary hypertension; Plt = platelet; PVR = pulmonary vascular resistance; RAP= right atrial pressure; SvO2
595	= mixed venous oxygen saturation; VTE = venous thromboembolism; WBC = white blood cell; WHO FC = World
596	Health Organization functional class.

	CHIP vs Non-CHIP HR (95% CI)	Р
Model 1	2.290 (1.428 - 3.672)	< 0.001
Model 2	2.161 (1.342 - 3.479)	0.002
Model 3	2.636 (1.415 - 4.912)	0.002
Model 4	3.447 (1.747 - 6.803)	< 0.001

598	Table 2. Results of multivariable Cox proportional hazards models examining the
599	relation of CHIP to the risk of all-cause death.

Model 1:unadjusted; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex, 6MWD, WHO FC,
NT-proBNP, RAP, SvO₂, PVR and CI; Model 4: adjusted for age, sex, 6MWD, WHO FC, NT-proBNP, RAP, SvO₂,
PVR, CI and treatment regimens. Treatment regimens represents whether or not patients underwent PEA/BPA
treatments. 6MWD = 6-minute walking distance; CHIP = clonal hematopoiesis of indeterminate potential; CI =
cardiac index; HR = hazard ratio; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PVR = pulmonary
vascular resistance; RAP= right atrial pressure; SvO₂ = mixed venous oxygen saturation; WHO FC = World
Health Organization functional class.

607 Figures




608

Figure 1. Diagram showing the selection of patients with CTEPH in the present study.

- 610 CHIP = clonal hematopoiesis of indeterminate potential; CTEPH = chronic
- 611 thromboembolic pulmonary hypertension. WES: whole-exome sequencing; WGS:
- 612 whole-genome sequencing.

613



615

Figure 2. The proportion of CHIP-related mutated genes in patients with chronic

- 617 thromboembolic pulmonary hypertension. CHIP = clonal hematopoiesis of
- 618 indeterminate potential.




Figure 3. Kaplan-Meier survival curve for all-cause death stratified by CHIP status in

622 chronic thromboembolic pulmonary hypertension. CHIP = clonal hematopoiesis of

623 indeterminate potential.






Figure 4. Inflammatory cytokines characteristics in patients of CHIP group/non-CHIP

627 group. CHIP = clonal hematopoiesis of indeterminate potential.






Figure 5. Inflammatory markers of IgG galactosylation distribution in CHIP
group/non-CHIP group patients. CHIP = clonal hematopoiesis of indeterminate
potential.